Navigation Links
BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Date:10/3/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Oct. 3 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's U.S. pivotal phase III MAESTRO-03 trial of dirucotide (MBP8298) in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the third of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

About MAESTRO-03

----------------

The MAESTRO-03 U.S. pivotal phase III clinical trial is a randomized, double-blind study that has completed recruitment of approximately 510 patients at 68 clinical sites who will be administered either dirucotide (MBP8298) or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 75% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... Worcester, Mass. (PRWEB) , ... July 06, 2015 ... ... by Worcester Polytechnic Institute (WPI), offers new insights into how virulent fungi adapt ... block their spread, and how that battle leaves them temporarily weakened. These insights ...
(Date:7/6/2015)... ... July 06, 2015 , ... Discovery ... diagnostic tests are key drivers of the global molecular diagnostics market. BCC Research ... the introduction of new companion diagnostic tests will increase demand for inexpensive and ...
(Date:7/6/2015)... ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) ... Novella Clinical (Novella), to conduct the phase 3 ... glioblastoma. Novella is a full-service, global clinical research organization ... oncology companies. The ICT-107 phase 3 trial will include ... Europe and Canada , ...
(Date:7/3/2015)... , ... July 03, 2015 , ... ... by Fortune 500 companies and professional service industries alike-- typically known for its ... clients laugh, honor a good cause and break from their day jobs. , ...
Breaking Biology Technology:Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 2Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 3Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 4Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 2Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 3ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2The Alexander Group Declares Their Independence with a Bit of Levity 2
... SAN DIEGO, Sept. 20 Cardium Therapeutics (NYSE Amex: ... Reinhard, Cardium,s Chairman and Chief Executive Officer will present ... to be held September 29-30, 2010 at the Radisson ... be webcast, investors can access a replay of the ...
... Epitomics, Inc. today announced that The Michael J. ... company to distribute a panel of LRRK2 monoclonal antibodies ... parties. Under a special arrangement the antibodies are being ... community to help advance LRRK2 therapeutic development efforts. The ...
... Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase... -- PARIS, September 20, ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so ...
Cached Biology Technology:Cardium to Present at 10th Annual Biotech in Europe Investor Forum 2Epitomics, Inc. Announces Worldwide Availability of LRRK2 Antibodies Developed in Partnership With The Michael J. Fox Foundation 2Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 2Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 3Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 4Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 5Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 6Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 7Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 8Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 9Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 10Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 11Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 12
(Date:6/30/2015)... 2015 To bolster its efforts and commitment to ... today the addition of two new team members. ... and David Raviv will act as head of ... commitment to providing the most secure solutions for the enterprise ... Layer 7 Technologies, a provider of security and management products, ...
(Date:6/25/2015)... -- According to a new market ... Technology, Material (Optical Prism, Piezoelectric, Capacitive & Adhesives), ... & Geography - Global Forecast to 2014 - ... expected to reach $14,500.07 Million by 2020, at ... 76 market Tables and 109 Figures spread through ...
(Date:6/24/2015)... , June 24, 2015 This report provides ... the next six years. It contains an analysis of ... along with their impact from the short, medium, and ... discusses the industry, market, and technology trends that currently, ... need of concerned authorities to efficiently manage the increasing ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... loss of blood flow to the spine returned to near ... spinal stem cells (hSSCs), researchers from the University of California, ... by Martin Marsala, M.D., UC San Diego professor of anesthesiology, ... journal Neuroscience, which is now online. , “We demonstrated that ...
... can reduce cardiovascular disease risks according to Penn State ... they are not currently included in the health claim ... as part of a healthy diet," says Dr. Amy ... nuts have higher levels of monounsaturated fats, like those ...
... is melting at a significantly faster rate than projected ... study concludes. The research, by scientists at the National ... Colorado's National Snow and Ice Data Center (NSIDC), shows ... than estimated by any of the 18 computer models ...
Cached Biology News:Human stem cell treatment restores motor function in paralyzed rats 2Human stem cell treatment restores motor function in paralyzed rats 3Hawaiian treasure, macadamia nuts good for the heart 2Arctic ice retreating more quickly than computer models project 2Arctic ice retreating more quickly than computer models project 3
... pLivSelect is a direct ... recombinant identification. Recombinant selection ... survival, eliminating the need ... This quick and inexpensive ...
... has been designed and created in order ... friendly genotyping analysis tool. We incorporated the ... into the software. Their main requirements were ... low acquisition cost. GeneMarker can perform ...
... through columns is a well-known separation technique ... applications are in DNA/RNA extraction in microbiology, ... purification in chemical or analytical laboratories. ... Genesis series instruments for smaller scales. The ...
... 3D structure visualization, phylogenetic tree building, sequence ... single application. Retrieve ... and filter them in real-time Organize ... searching, filtering and sorting Provides up-to-date ...
Biology Products: